Metastatic Crohn’s Disease Often Precedes Intestinal Diagnosis : Gut | June 2026

Introduction:

Metastatic Crohn’s disease (MCD), also referred to as cutaneous or genital Crohn’s disease, is a rare extraintestinal manifestation characterized by granulomatous skin inflammation occurring at sites separate from the gastrointestinal tract. Because of its rarity and heterogeneous presentation, MCD is frequently underrecognized and may lead to significant diagnostic delays. Current knowledge regarding its epidemiology, clinical characteristics, and optimal management remains limited, largely due to the absence of large prospective studies.

Problem Statement:

The rarity of MCD and the predominance of case reports and small case series have hindered the development of standardized diagnostic and therapeutic approaches. Clinicians often face uncertainty regarding recognition of disease patterns, identification of at-risk patients, and selection of effective treatment strategies.

Summary:

This systematic review represents one of the most comprehensive evaluations of metastatic Crohn’s disease to date, compiling data from over 600 reported patients. The analysis demonstrated that MCD predominantly affects younger individuals and is more common in women. Genital erythema and edema emerged as the hallmark clinical manifestations, with disease frequently involving the genitalia, perineum, and groin. Importantly, one of the most clinically relevant findings was that approximately one-third of patients developed MCD before receiving a diagnosis of luminal or perianal Crohn’s disease. This observation highlights the importance of considering Crohn’s disease in the differential diagnosis of unexplained granulomatous genital or cutaneous lesions, even in the absence of gastrointestinal symptoms. The review also identified associations with colonic Crohn’s disease and perianal involvement, suggesting a distinct disease phenotype. Ulceration appeared to be a marker of more severe and extensive disease. Therapeutic approaches varied widely and included topical therapies, systemic immunosuppressive agents, biologic therapies, and surgical interventions, reflecting the lack of evidence-based treatment guidelines. Anti-TNF agents were the most frequently reported advanced therapy. Overall, the findings underscore the need for increased clinical awareness, standardized reporting, and prospective studies to establish effective diagnostic pathways and treatment algorithms for this challenging manifestation of Crohn’s disease.